Crescent Biopharma FDA clears IND for CR-002
Crescent Biopharma says the FDA cleared its IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC for solid tumors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.